ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 5. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels / The Criteria Committee of the New York Heart Association. 9 th ed. Boston: Little Brown, 1994. 6. Hawwa N, Vest AR, Kumar R, Lahoud R, Young JB,Wu Y, et al.Comparison between the Kansas city cardiomyopathy questionnaire and New York Heart Association in assessing functional capacity and clinical outcomes. J Card Fail. 2017;23(4):280-5. 7. Butler J, Gheorghiade M, Metra M. Moving away from symptoms-based heart failuretreatment:misperceptionsandrealrisks forpatientswithheart failure. Eur J Heart Fail. 2016;18(4):350-2. 8. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;53(15):e1-90. 9. Writing GroupMembers, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics-2016 update: a report from the AmericanHeart Association. Circulation. 2016;133(4):e38-360. 10. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW.Quantifyingtheheart failureepidemic:prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25(18):1614-9. 11. Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, Butler J, Filippatos G. Reframing the association and significance of co- morbidities in heart failure. Eur 2016;18(7):744-5. 12. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30-41. 13. Bocchi EA, Arias A, VerdejoH, DiezM, Gómez E, Castro P; Interamerican Society of Cardiology. The reality of heart failure in Latin America. J Am Coll Cardiol. 2013;62(11):949-58. 14. Shen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, et al. Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail. 2017;10(11):pii:e004361. 15. Albuquerque DC, Neto JD, Bacal F, Rohde LE, Bernardez-Pereira S, Berwanger O, et al; Investigadores Estudo BREATHE. I Brazilian Registry of Heart Failure - Clinical aspects, care quality and hospitalization outcomes. Arq Bras Cardiol. 2015;104(6):433-42. 16. Jorge AL, Rosa ML, Martins WA, Correia DM, Fernandes LC, Costa JA, et al. The prevalence of stages of heart failure in primary care: a population- based study. J Card Fail. 2016;22(2):15. 17. StevensonLW,PerloffJK.The limitedreliabilityofphysicalsignsforestimating hemodynamics in chronic heart failure. JAMA. 1989;261(6):884-8. 18. Rohde LE, Beck-da-Silva L, Goldraich L, Grazziotin TC, Palombini DV, Polanczyk CA, et al. Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Can J Cardiol. 2004;20(7):697-702. 19. WangCS,FitzGerald JM,SchulzerMM,MakE,AyasNT.Doesthisdyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294(15):1944-56. 20. Girerd N, Seronde MF, Coiro S, Chouihed T, Bilbault P, Braun F, et al. Integrative assessment of congestion in heart failure throughout the patient journey. JACC Heart Fail. 2018;6(4):273-85. 21. MarantzPR,TobinJN,Wassertheil-SmollerS,SteingartRM,WexlerJP,BudnerN, etal.Therelationshipbetween leftventricularsystolicfunctionandcongestive heartfailurediagnosedbyclinicalcriteria.Circulation.1988;77(3):607-12. 22. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-7. 23. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish A, Chen A, Krauser D, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-54. 24. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005;7(4):537-41. 25. Kelder JC, CramerMJ, vanWijngaarden J, van Tooren R, MosterdA, Moons KG, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124(25):2865-73. 26. Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. The British journal of general practice : the journal of the Royal College of General Practitioners. 2006;56(526):327-33. 27. Booth RA, Hill SA, Don-Wauchope A, Santaguida PL, Oremus M, McKelvie R, et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev. 2014;19(4):439-51. 28. Hogenhuis J, Voors AA, Jaarsma T, Hoes AW, Hillege HL, Kragten JA, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail. 2007;9(8):787-94. 29. Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006;47(3):582-6. 30. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571-9. 31. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC, Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40(5):976-82. 32. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. AmHeart J. 2006;151(5):999-1005. 33. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J AmColl Cardiol. 2013;61(14):1498-506. 34. Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, et al. prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68(2):2425-36. 35. Savarese G, Musella F, D'Amore C, Vassallo E, Losco T, Gambardella F, et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail. 2014;2(2):148-58. 36. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015 Mar 4;350:h910. 37. Ezekowitz JA, O'Meara E, McDonaldMA, Abrams H, ChanM, Ducharme A, et al. 2017 Comprehensive update of the canadian cardiovascular society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342-433. 38. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66-74. 517